This paper is incredibly detailed and should provide the information you need to get PERC working well for RNP delivery ex vivo using Cas9 or Cas12a. The big idea is to omit the electroporator and instead mix your RNP enzyme with an inexpensive and easy-to-use peptide.

We also built an FAQ page with some complementary resources, including recommendations on sourcing protein & peptide. We will continue updating this page with new information. Check it out!
www.rosswilsonlab.org/perc

Credit goes to everyone who contributed: Srishti Sahu, Lorena de Oñate, Bruno Solano, and especially lead author Christy George, who worked tirelessly on this review.

Ex vivo therapies have predominated so far because they sidestep the substantial challenges of in vivo delivery. As potent as cell therapies can be, transplant can limit access and delay treatment. Fortunately, off-the-shelf T cell therapies and in vivo delivery are poised to change this landscape.

Therapeutic genome editing of hematopoietic stem cells (HSCs) and T cells has been getting better and better over the last ~15 years, with progress greatly accelerated by the advent of CRISPR. Here's our timeline figure in presentation-friendly "landscape" format (an online exclusive 🤗)